Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04717453 · ClinicalTrials.gov registry record
Study to Characterize Rate of Ureagenesis in Patients With Ornithine Transcarbamylase (OTC) Deficiency
A clinical trial, sponsored by Ultragenyx Pharmaceutical.
- Terminated
- Registry status
- 1
- Enrollment target
NCT04717453: Clinical Trial study, sponsored by Ultragenyx Pharmaceutical.
NCT04717453 is a clinical trial that was terminated before completion, run by Ultragenyx Pharmaceutical. The registered enrollment target is 1 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04717453 was terminated before completion, sponsored by Ultragenyx Pharmaceutical.
- TERMINATED
- Registry status
- 1 participants
- Enrollment target
Study Summary
The objectives of the study are to characterize urea production rates in patients with OTC, characterize the association of rate of ureagenesis and disease severity in OTC patients, characterize the association of rate of ureagenesis and executive and verbal function and characterize the association of rate of ureagenesis and patient-reported functional status.
Primary Outcome
Urea excretion after ingestion of sodium acetate as measured in blood
Interventions
- OTHER No Intervention
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2020-10-06 |
| Est. Completion | 2021-12-15 |
Why NCT04717453 stopped before completion
NCT04717453 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 1 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which No Intervention is the first listed.
NCT04717453 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04717453 about?
NCT04717453 is a clinical study titled "Study to Characterize Rate of Ureagenesis in Patients With Ornithine Transcarbamylase (OTC) Deficiency". The objectives of the study are to characterize urea production rates in patients with OTC, characterize the association of rate of ureagenesis and disease severity in OTC patients, characterize the association of rate of ureagenesis and executive and verbal function and characterize the association...
What is the current status of trial NCT04717453?
This trial is currently terminated. The enrollment target is 1 participants. The study started on 2020-10-06. Estimated completion is 2021-12-15.
What interventions are being tested in trial NCT04717453?
The interventions under investigation include: No Intervention (OTHER).
Who is sponsoring clinical trial NCT04717453?
This trial is sponsored by Ultragenyx Pharmaceutical, which has 52 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI